Literature DB >> 31296800

[Techniques and Outcomes of Segmentectomy for Non-small Cell Lung Cancer].

Ryota Myobatake1, Hiroyoshi Tsubochi, Tomoyuki Nakano, Kentaro Minegishi, Shunsuke Endo.   

Abstract

BACKGROUND: The most important step in lung segmentectomy is to determine an appropriate intersegmental plane to obtain sufficient pre- and intraoperative margins. Inappropriate dissection of the lung parenchyma leads to loss of oncological validity and additionally causes various complications such as pneumonia, prolonged air leakage, lung congestion, and atelectasis.
OBJECTIVES: In this study, we evaluated the validity of segmentectomy for non-small cell lung cancer (NSCLC) based on evaluation of survival outcomes and recurrence patterns. OPERATIVE TECHNIQUE: In principle, we usually perform video-assisted thoracic surgery segmentectomy. Hilar dissection is performed along the intersegmental vein under ultrasonographic guidance, and the peripheral lung parenchyma is subsequently stapled. We usually create inflation-deflation lines from before to determine the intersegmental lines. Recently, near-infrared fluorescence imaging with indocyanine green is also used.
METHODS: We retrospectively reviewed data of 101 patients who underwent segmentectomy for lung cancer between 2007 and 2014.
RESULTS: The 5- and 10-year overall survival rates were 84% and 62%, respectively. The 5- and 10-year recurrence-free survival rates were 83% and 63%, respectively. Recurrence at the surgical margin occurred in 5 patients( pulmonary stump:4 patients, bronchial stump:1 patient).
CONCLUSION: Segmentectomy may be acceptable for patients with Stage I NSCLC. Accurate determination of the intersegmental plane is essential to avoid stump recurrence.

Entities:  

Mesh:

Year:  2019        PMID: 31296800

Source DB:  PubMed          Journal:  Kyobu Geka        ISSN: 0021-5252


  1 in total

1.  Surgery and subsequent risk of non-small cell lung cancer recurrence: a meta-analysis of observational studies.

Authors:  Jia Hu; Huikai Miao; Rongzhen Li; Zhesheng Wen
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.